Article
Author(s):
“We’re going to review CHEK2-related management guidelines, hereditary cancer implications for males and their families…and the importance of cascade testing,” says Veda N. Giri, MD.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
In this video, Veda N. Giri, MD, previews the upcoming ENGAGEMENT study virtual genetics board’s February case discussion (https://www.prostategenetics.com/engagement). Giri is a Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
2 Commerce Drive
Cranbury, NJ 08512